Akari Therapeutics Plc price to book ratio AKTX

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026: 34.4×
10-year median: 0.1×
Against its 10-year history: 91st; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.0× to 58.2×
Peer median: 2.3×

Akari Therapeutics Plc's price to book ratio is 34.4× as of Oct 23, 2026.

That is above its ten-year median of 0.1×, higher than on 91% of days in the last ten years.

Over that time it ranged from 0.0× in Mar 2018 to 58.2× in May 2026.

The median for 10 large drugmakers of a similar size is 2.3×.

Price to book ratio over time

median 0.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	34.4×	0.1×	58.2×
2025	0.4×	0.4×	2.0×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	0.0×	0.0×	0.1×
2017	0.1×	0.0×	0.3×
2016	0.1×	0.1×	0.2×
2015	0.2×	0.0×	0.3×

Against its peers

Companies in Drug Manufacturers - General nearest Akari Therapeutics Plc's size, closest first, today.

Company	Price to book ratio
AKTXAkari Therapeutics Plc	34.4×
CRMDCorMedix	1.3×
ZVRAZevra Therapeutics	2.7×
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	4.1×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
ARVNArvinas	0.8×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
PCRXPacira BioSciences	2.2×
Peer median	2.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Akari Therapeutics Plc

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.